About us

 

 

Latest News

Blueprint Genetics welcomes new investors!

Download PDF

 

Our company

We do high quality genetics testing for a global clinical community. By combining a state of the art laboratory process, the latest sequencing technology, AI empowered data-crunching tools and techniques, world-class professionals and a holistic customer experience approach, we are leading the way of changing mainstream healthcare of tomorrow.

Our promise

We provide clinicians, and their patients, with comprehensive and high-quality tools and resources for diagnostics of genetic conditions. In doing so, we provide possibilities for targeted treatment and individualized care for patients.

 

Key Facts

Based In

 

Helsinki

San Fransisco

Dubai

100+
Employees
800
Clinicians in 40 countries
Founded In
2012
Quality Management
CLIA
Clinical laboratory certification by US regulatory authority
CAP
All laboratory functions accredited by College of American Pathologists
ISO 15189
Our processes and documentation comply with the most widely used standards worldwide

Founders

Tommi Lehtonen

Tommi Lehtonen

Chief Executive Officer

Tommi is the CEO and co-founder of Blueprint Genetics, a clinical genetics company based in Helsinki, San Francisco, and Dubai. He has been running Blueprint Genetics since the beginning and is responsible for sales management, business development and financing. Tommi spends time in Bay Area regularly and is a regular speaker in life science and tech conferences in both US and Europe. Prior to Blueprint Genetics, Tommi founded a data analytics company called Whitevector and grew it to the Nordics and UK. Tommi holds a M.Sc. (Tech) from the Helsinki University of Technology where he studied business strategy and applied mathematics.
Juha Koskenvuo

Juha Koskenvuo

Laboratory Director, Chief Medical Officer, MD, Ph.D.

Juha is the Laboratory Director and Chief Medical Officer of Blueprint Genetics. He is a co-founder of the company as well. Juha is responsible for supervising laboratory production and for designing new diagnostic tests. On a daily basis, he participates in the clinical evaluation of genetic findings and further develops the company's variant classification and interpretation practices in collaboration with a team of geneticists. Juha has a MD-PhD from the University of Turku. In 2006, Juha completed his fellowship program in clinical physiology and nuclear medicine. The following year, he became a docent. From 2007 to 2009, he joined the UCSF Cardiac Stem Cell Translational Development Program (California, USA) as a post-doctoral researcher and later as a research specialist. He also teaches at the University of Helsinki.
Samuel Myllykangas

Samuel Myllykangas

Chief Operations Officer, Ph.D.

Samuel is the Head of Operations at Blueprint Genetics as well as a co-founder of the company. He is an expert in genome analysis technologies and has extensive experience in bioinformatics and cancer genomics research. Samuel received his PhD from the University of Helsinki and completed his post-doctoral research at Stanford University. At Stanford, he developed high-throughput sequencing technologies such as the Oligonucleotide-Selective Sequencing (OS-Seq™). He is an adjunct professor in genetics at the University of Helsinki, an author of several high-impact publications, and an inventor in patents of DNA sequencing methods.
Tero-Pekka Alastalo

Tero-Pekka Alastalo

President, Chief Medical Officer, MD, Ph.D.

Tero-Pekka is the Chief Medical Officer, President, and a co-founder of Blueprint Genetics. He is based in San Francisco and in charge of North American operations. He designs diagnostic panels and mutation databases and works with clinical evaluation of genetic data. Tero-Pekka has a MD-PhD degree and is specialized in pediatrics and pediatric cardiology. He has a PhD in molecular and cellular biology as well. In 2007, he continued his research at Stanford University, School of Medicine. During this three year postdoctoral training, he focused on the molecular genetic mechanisms of cardiovascular diseases. He continued his cardiovascular research at the University of Helsinki as a principal investigator and the head of an academic research group.

 

Subscribe to our newsletter


 

News

Blueprint welcomes new investors!

Published on July 11, 2017

We are extremely happy to welcome two new investors on board Blueprint Genetics. Our new partners are Creathor, a venture fund based in Germany, and MTIP (MedTech Innovation Partners), a venture fund based in Switzerland. Our existing investors are also participating in the funding round that totals €14m. As a…

Read more

See all news

Events

SLUSH

Messuaukio 1, 00520 Helsinki, Finland

Slush brings together the leading actors of the global tech scene to Helsinki for something very special. Described by many as “Burning Man meets TED”, the event has grown in just a few short years to 20,000 attendees and 1 million live stream viewers. In 2017, over 2,600 startups,…

Read more

See all events
Last modified: 05.18.2018